Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
The Pharmaceutical Rivalry Behind the Weight-Loss Drug Boom | Big Take
Posted
January 26, 2024
Views
403
Likes
8
Engagement
1.99%
January 26, 2024
403
8
1.99%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
13:49Now PlayingThe weight-loss drug market has ballooned to $80 billion. And the two pharmaceutical companies currently duking it out for market dominance, Novo Nordisk and Eli Lilly, have a century-long rivalry.
Bloomberg News health reporter Madison Muller breaks down how Eli Lilly developed Zepbound, a new drug that can help patients cut more than 20% of their body weight — and why some investors and analysts think it will turn Eli Lilly into the first ever trillion-dollar drug company.
See omnystudio.com/listener () for privacy information.
Each weekday, The Big Take brings you one story—one big, important story. Host Wes Kosova talks to Bloomberg journalists around the world, experts and the people at the center of the news to help you understand what’s happening, what it means and why it matters. Money, politics, the economy and business, energy, the environment, technology—we cover it all on The Big Take.
Subscribe to Bloomberg Podcasts
Listen to more of The Big Take
#Bloomberg #Podcast #TheBigTake
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
